Table III.

HPV in OSSN.

Author (Refs.)	Date of publication	HPV prevalence	HPV types	Method of detection	Sample size	HIV status
Lauer et al (70)	1990	80%	16, 18	PCR	5	-
Tuppurainen et al (71)	1992	0%	-	PCR/ISH	4	-
McDonnell et al (20)	1992	88%	16	PCR	42	-
Tabrizi et al (72)	1997	39%	6, 11, 16, 18	PCR	88	-
Karcioglu et al (73)	1997	55.6%	16,18	Nested PCR, SB	45	-
Dushku et al (22)	1999	0	-	Nested PCR	8	-
Toth et al (74)	2000	22%	16, 18	PCR/IHC	23	-
Scott et al (75)	2002	100%	16, 18	PCR/ISH	10	-
Eng et al (76)	2002	0%	-	Nested PCR	20	-
Tulvatana et al (77)	2003	0%	-	PCR/dot hybridization	30	-
Ateenyi-Agaba et al (27)	2004	86%	EV-HPV types	PCR	21	-
Moubayed et al (78)	2004	93%	6, 11, 18	ISH immunomax	14	64,2%
Tornesello et al (79)	2006	19.8%	6, 18, EV-related HPVs, CJ198	PCR	86	65,1% (25% HPV+)
Kuo et al (29)	2006	100%	6, 11, 16, 18, 33, 37, 58, 72	Nested PCR	9	-
Sen et al (80)	2007	0%	-	IHC	30	-
De Koning et al (81)	2008		38% Genital (both high and low risk). 22% cutaneous types	PCR	81	(48% HPV+)
Manderwad et al (82)	2009	0%	-	PCR/ISH-CARD	57	-
Guthoff et al (34)	2009	0%	-	PCR/IHC	31	No HIV patients
Ateenyi-Agaba et al (14)	2010		Mucosal HPV: 6,4% SCC; 7,7% dysplasia cutaneous HPV: 44,7% SCC; 41% dysplasia	PCR 39 dysplasia	94 SCC	Uncertain role of HIV
Asadi-Amoli et al (83)	2011	88%	No type found	Nested PCR	50	-
Chauhan et al (84)	2012	11%	16	PCR	64	-
Woods et al (85)	2013	6.5%	16	Nested PCR	50	-
Afrogheh et al (86)	2016	30%	16	IHC, ISH, PCR	43	?

HPV, human papillomavirus; OSSN, ocular surface squamous neoplasia; ISH, in situ hybridization; CARD, catalyzed reporter deposition; IHC, immunohistochemistry; SCC, squamous cell carcinoma.